Articles tagged with Lung Cancer
The UK Lung Screening Trial (UKLS) found a significant reduction in lung cancer mortality among high-risk groups through low-dose CT screening. The study, which included over 4,000 participants, showed a 16% relative reduction in lung cancer deaths.
A genomic analysis of lung cancer in people with no smoking history identified three molecular subtypes, including the slow-growing 'piano' subtype and the aggressive 'forte' subtype. The study aims to guide clinical treatments based on these subtypes, which may have different prevention and treatment approaches.
A novel AI-powered blood test, DELFI, has been developed to detect lung cancer with high accuracy. The test uses machine learning to analyze cell-free DNA in the bloodstream and has been shown to identify over 90% of patients with lung cancer.
Researchers have developed a prediction model that uses radiomic features from pre-treatment CT scans combined with clinical data to identify patients who are not likely to respond to immunotherapy. The model divides patients into four risk groups, including those with very high and low risks of death following immunotherapy.
A research team from Okayama University has reported the potential of a berry-producing vine, Vitis coignetiae Pulliat (Yamabudo), against lung cancer in mice. The study found that extracts from Yamabudo and its chemical compounds display tumor-suppressing properties by repairing DNA damage and suppressing growth signaling pathways.
Scientists investigated a method to enhance immunotherapy for lung cancer and found that combining it with certain chemotherapy drugs could eliminate harmful immune cells. This approach showed promising results in preclinical studies, inducing the regression of about 70% of tumors.
Researchers from UNC School of Medicine, MAHEC, and community partners will address racial disparities in maternal care by improving data accountability and providing community-based doula support. The study aims to decrease pregnancy complications for Black women and improve outcomes in maternal care.
A new therapy, amivantamab, has demonstrated a 40% overall response rate in patients with non-small cell lung cancer and the rare EGFR Ex20Ins mutation. The median duration of response was 11.1 months, offering a potential cure for previously untreatable cases.
The European Respiratory Society has announced the press registration and program for its upcoming International Congress 2021. Over 4,000 presentations on various lung health topics will be presented during the event.
A prospective cohort study found that quitting smoking after being diagnosed with early-stage non-small cell lung cancer can slow disease progression and decrease mortality. Patients who quit smoking lived longer overall, had a longer time to death from lung cancer, and experienced improved survival without cancer recurrence.
A study led by D. Ross Camidge found that MET amplification drives a rare subtype of non-small cell lung cancer, which responded to crizotinib therapy. The research also highlights the importance of MET amplification testing and therapies for this unique patient population.
A study by CNIO researchers found that both isoforms of the KRAS oncogene are oncogenic and must be targeted for therapies to be effective. The research suggests that KRAS4A mutant is even more active than previously thought, inducing lung cancer and metastasis in 20% of individuals.
The study found that AIM2 inflammasome is at the intersection of COPD and lung cancer, with higher expression correlating to lower survival rates in smoking COPD adenocarcinoma patients. This suggests that the AIM2 inflammasome may be a potential target for developing novel treatments for COPD patients who develop lung cancer.
Scientists at Sinai Health discover that all cancers fall into two categories based on the presence or absence of YAP. This binary rule reveals different drug sensitivities and resistance in each classification, offering a new strategy for treating aggressive forms of cancer.
A recent study published in the American Journal of Roentgenology found that reduced-dose CT scans can detect greater than 90% of lung nodules in children and young adults with cancer. This could lead to a reduction in patient dose while maintaining high diagnostic accuracy.
Researchers identified a potential biomarker, A20 protein, that can predict the success of immunotherapy in treating lung cancer. Patients with low A20 expression are less likely to respond to treatment and have poorer survival rates.
Researchers found that MET oncogene amplification creates a hostile environment for immunotherapy, making it ineffective in treating some lung cancers. A combination of a MET inhibitor and anti-PD1 immunotherapy was effective in treating cancers with MET amplification.
A large long-term study found that individuals with high physical activity levels and healthy sleep patterns had lower risks of death from heart disease, stroke, and cancer. Those who were physically inactive and had poor sleep quality were most at risk of dying from these causes.
New research reveals how lung cancer progression disrupts circadian glucose regulation, fueling cancer cell growth. The study identifies REV-ERB? as a key regulator and suggests targeting this protein to suppress cancer cell growth.
A study published in Journal of Thoracic Oncology found that low-dose computed tomography (LDCT) screening for primary lung cancer is associated with a lower risk of developing brain metastases. Researchers identified 1502 participants diagnosed with lung cancer between 2002 and 2009, where LDCT screening was detected versus other meth...
Researchers at Moffitt Cancer Center have developed a non-invasive method to measure PD-L1 biomarker levels in lung cancer patients using PET/CT scan images. This approach uses deep learning to predict checkpoint inhibitor outcomes, which could help determine optimal treatment strategies for patients.
Researchers at Mount Sinai Hospital discovered that early-stage lung cancer tumors hijack immune cells called tissue-resident macrophages to facilitate their invasion of lung tissue. This process allows the tumor to evade the immune system and grow into more deadly stages of cancer.
The LMO1 gene codes for a protein that regulates RNA production and is implicated in cancer formation. Researchers found that overexpression of LMO1 is associated with poor patient outcomes in different cancers. Further study of LMO1 may lead to targeted therapies for various types of cancer.
A modeling study found that schools can reopen safely with controlled community transmission and moderate mitigation strategies in place. Asymptomatic screening is one identified strategy to facilitate reopening while minimizing transmission risk.
The FDA-approved drug sotorasib has been shown to reduce tumor size and improve survival among patients with non-small-cell lung cancer caused by a specific DNA mutation. The study involved 126 patients who showed significant responses to the treatment, including 34% achieving partial response and 3% complete response.
A new study published in the Journal of Thoracic Oncology found that using traditional methods like BMI can misclassify obesity as a non-risk factor for lung cancer. The researchers measured visceral fat index through CT scans and found a clear correlation between central obesity and poor lung cancer outcomes.
A new study found that delaying lung cancer surgery for more than 12 weeks after diagnosis is associated with a higher risk of recurrence and death. Patients who underwent surgery within this time frame lived 7.5 months longer than those who delayed treatment.
The acylfulvene alkylating agent LP-184 demonstrates highly potent anticancer activity in NSCLC cell lines, correlating with PTGR1 transcript levels. It targets tumors regardless of co-occurring mutations but is especially effective in KEAP1 mutant settings.
A new AI algorithm accurately predicts lung cancer risk from low-dose CT scans, outperforming established models and human clinicians. The algorithm may aid in optimizing follow-up recommendations for lung cancer screening participants.
A new study reveals that breast cancer survivors have a 20-44% higher risk of developing new cancer diagnoses compared to healthy individuals. The research identifies specific breast cancer subtypes and diagnosis ages associated with increased risk of subsequent primary cancers.
A lack of insurance leads to worse cancer survival across the 16 most common cancers, with uninsured patients 60-64 facing significantly poorer outcomes than their older counterparts. This disparity is driven by the high costs of newer potentially lifesaving treatments, which can be unaffordable for those without insurance.
Research suggests that implementing ATS-recommended air quality standards could prevent tens of thousands of deaths, lung cancer cases, and illnesses. By meeting these standards, the US could avoid an estimated 14,650 deaths, 2,950 lung cancer cases, and 33,000 additional illnesses annually.
A retrospective study found that CT features can help select patients with stage IA non-small cell lung cancer for sublobar resection. Peritumoral interstitial thickening and pleural contact were independently associated with pathologic lymphovascular invasion, predicting recurrence-free survival after the procedure.
Researchers created a spatial atlas of early-stage lung cancer and normal lung tissue at single-cell resolution, providing insights into tumor development and immune cell interactions. The study identified CD24 as a new immunotherapy target for lung cancer treatment, correlating with poor clinical outcomes and shortened survival.
Researchers found that a commonly used risk-prediction model for lung cancer does not accurately identify high-risk Black patients who could benefit from early screening. The study, published in JAMA Network Open, aimed to strengthen the argument for more inclusive guidelines for screening eligibility.
A new study by UCLA researchers identified a novel combination therapy using immune checkpoint inhibitors with ATRA to potentially overcome resistance to immunotherapy in LKB1-deficient lung cancer. The therapy led to eradication of over 70% of tumors and generated durable tumor-specific immunity.
A study by Penn State researchers found that people who felt pleasure in a controversial celebrity's misfortune were less likely to take steps to prevent lung cancer or COVID-19. The study suggests that schadenfreude can demotivate people from taking preventive actions, having serious public health implications.
Researchers at VCU Massey Cancer Center have identified a protein called PLK3 that operates with mutated p53 genes to spur lung cancer growth. Inhibiting PLK3 has been shown to reduce tumor cell formation and proliferation in preclinical models of lung cancer.
Researchers found that patients with high levels of PDL-1 and a KRAS gene mutation lived longer when treated with immunotherapy alone compared to those without the mutation. Patients without the mutation had better survival with combination therapy, suggesting preferred treatment approaches for this patient group.
Researchers at Wake Forest School of Medicine have identified a set of new genetic markers that could lead to targeted treatments for non-small cell lung cancer. The study found that tumors with mutated KMT2 genes exhibit genetic instability, making them more sensitive to PARP inhibitors.
A team of researchers has developed AI tools to predict which lung cancer patients will respond to immunotherapy, with the goal of improving patient outcomes and reducing costs. The study uses machine learning algorithms to analyze tissue scan patterns and identify previously unseen indicators that can inform treatment decisions.
The cancer burden in China has undergone a paradigm shift, with rising cases of breast and lung cancers. The country's high incidence rate makes it a priority for policymakers to implement tailored preventive measures, including health education, vaccination programs, and tobacco-control policies.
Researchers found a novel genomic signature associated with increased risk of early death from lung cancer. Patients with high expression of these genes have indicators of immune system activity, but also suppressed T cells, which can impact treatment effectiveness.
Two researchers from the University of Minnesota Medical School will lead a new VA-funded network to expand lung cancer screenings and research among veterans in the Upper Midwest region. The $4.5 million grant aims to increase veteran access and participation in lung cancer clinical trials, addressing barriers such as distance travel,...
The IASLC Molecular Database Project seeks to accelerate understanding of lung cancer biology, clinical care, and global scale. It aims to provide a platform for deeper, broader understanding of molecular testing and targeted therapy.
The new guidelines recommend yearly low-dose CT scans for Americans aged 50-80 with a 20 pack-year smoking history or those who quit less than 15 years ago. The expanded criteria aim to reduce lung cancer disparities in Black people and women.
Updated USPSTF guidelines based on age, pack-years, and quit-years exacerbate eligibility disparities among racial and ethnic minorities. However, incorporating certain risk prediction models may help mitigate these inequalities, according to a study published in the American Journal of Roentgenology.
A new study found that a second drug targeting KRASG12C showed promising results in treating non-small-cell lung cancer (NSCLC) with this specific mutation. Nearly half of patients evaluable for clinical activity had a partial response to treatment, setting up potential future trials and combinations.
A new lymph node collection kit has been shown to improve long-term survival after curative-intent lung cancer surgery. The kit helps surgeons attain complete resection by improving pathologic nodal evaluation, leading to a significant increase in R0 resections and reduction in non-examination of lymph nodes.
Researchers discovered that glucose metabolism in tumor-associated neutrophils determines their tumor-supportive behavior in lung cancer development. Removing Glut1 from these cells reduces tumor growth rate but increases radiotherapy efficacy.
Researchers at Baylor College of Medicine have identified 25 rare genetic variants associated with increased risk of lung cancer. These variants, which include insertions and deletions, lead to genomic instability and increase DNA damage, suggesting a potential role in cancer development.
A study reveals that over one in ten lung cancer patients are unsure of their tumor type, highlighting the need for improved communication between patients and healthcare providers. Language differences and complex treatments contribute to these misunderstandings, jeopardizing patient care.
Golfers Against Cancer funds three CU Cancer Center researchers: Matthew Sikora studying genetic predispositions to ovarian cancer, Jamie Studts exploring lung cancer screening access, and Jenna Sopfe developing a standardized approach to sexual dysfunction in pediatric cancer survivors.
Experts recommend shared decision-making between patients and doctors before low-dose CT scans for lung cancer screening to ensure informed consent. The process can promote patient engagement, tobacco cessation, and screening adherence, leading to greater health equity.
A comprehensive review of lung cancer screening trials reveals both benefits and harms, leading to updated USPSTF recommendations. Screening can lower lung cancer deaths in high-risk individuals, but also leads to false positives and unnecessary procedures.
Researchers developed a new method to detect circulating tumor cells in NSCLC patients, identifying a CK-negative CTC population associated with metastasis and drug resistance. The use of hexokinase-2 as a biomarker revealed this novel CTC population in 50% of analyzed patients.
The new USPSTF recommendation doubles the number of eligible adults for lung cancer screening from 6.4 million to 14.5 million. However, experts argue that this expansion may not address racial inequities and highlights the need for individualized risk assessment and genetic risk models.
Researchers at KIST discovered that red ginseng can significantly suppress lung cancer metastasis, with components Rk1 and Rg5 showing effective inhibition. The study developed a microwave processing method to increase the concentration of these components, leading to potential anti-cancer effects.
A team led by Dr. Brian Brown is developing a CAR T-cell therapy that specifically targets immune-suppressing macrophages in tumors, clearing the way for other T cells to destroy cancer cells. The grant aims to advance this promising approach and bring new hope to patients with solid tumor cancers.
Moffitt researchers found that epithelial and mesenchymal subtypes of lung cancer cells respond differently to KRASG12C inhibitor therapy, with varying levels of sensitivity. The study suggests that targeting alternative signaling pathways, such as HER2 and FGFR1, may enhance treatment efficacy.